FDA Clearance Tracker · K202228
Omron Model BP7900 Blood Pressure Monitor + EKG
Last checked: Nov 20, 2026Latest source record: Apr 1, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Apr 1, 2021
Substantially Equivalent
Time to decision
237 days
Received Aug 7, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K202228
- Device name
- Omron Model BP7900 Blood Pressure Monitor + EKG
- Applicant
- Omron Healthcare, Inc.
- Applicant location
- Lake Forest, IL
- Received
- Aug 7, 2020
- Decided
- Apr 1, 2021
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 870.1130
- Specialty
- Cardiology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code DXN. The earliest in FDA's data is K760930, decided Nov 9, 1976.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K202228
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Omron Healthcare, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261929 · Decided Sep 10, 2026 · 93 days after receipt
Device type: System, Measurement, Blood-Pressure, Non-Invasive (DXN) · Cardiology
DEN230076 · Decided Oct 8, 2024 · 330 days after receipt
Device type: Oscillometric-Based, Over-The-Counter, Atrial Fibrillation Notification Feature (QXY) · Cardiology
K183215 · Decided Sep 7, 2019 · 292 days after receipt
Device type: Stimulator, Nerve, Transcutaneous, Over-The-Counter (NUH) · Neurology & Neurosurgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.